January 23, 2023

Dear Rett Syndrome Community,

Today we are excited to share the news that the FDA has cleared Neurogene’s Investigational New Drug (IND) application for NGN‐401 for the treatment of children with Rett syndrome. NGN‐401 is an investigational adeno‐associated virus (AAV) gene therapy candidate to be administered to pediatric patients that uses Neurogene’s Expression Attenuation via Construct Tuning (EXACT) gene regulation technology. The full press release issued today may be found at https://www.neurogene.com/news/

We realize you may have several questions upon hearing this news. The purpose of this letter is to help answer some of those questions.

First, Neurogene would like to express our gratitude to the entire Rett syndrome community for your recent participation in the survey shared by the Rett Syndrome Research Trust (RSRT) and the International Rett Syndrome Foundation (IRSF), as well as the many families we had the honor to speak with after completing the survey. Nearly 200 responses were received within the first few hours of the survey launching online! Your enthusiastic response is appreciated and was added to the input received from Rett syndrome clinical experts and the FDA, which helped to inform the clinical trial design, the IND submission, and our continued learning about how Rett syndrome impacts individuals and their families. We are also grateful to the Rett syndrome patient organizations in the US, the International Rett Syndrome Foundation and the Rett Syndrome Research Trust, for providing expertise and input which was critical to us reaching this important milestone.

**What does a cleared IND mean for a clinical trial?**

- Clearance of an IND by the FDA is a major milestone in advancing development of a new, investigational treatment
- It means that the US regulatory agency, the FDA, has provided approval for Neurogene to begin a clinical trial of the investigational gene therapy, NGN‐401

**What age range will be studied in this first clinical trial for NGN‐401?**

- This first clinical trial will study the investigational gene therapy, NGN‐401, in female children with Rett syndrome
- Additional details will be available when enrollment begins

**Will there be a clinical trial for boys?**

- For this initial clinical trial, the FDA has approved initiation of a clinical trial in pediatric females with Rett syndrome
- Decisions regarding additional clinical trials will be shared with the Rett community when the information becomes available

**How many participants will be included in the clinical trial?**

- This initial clinical trial will enroll a limited number of participants; more details will be provided once enrollment begins. These details will be posted on clinicaltrials.gov once they become available.
Where will the clinical trial be conducted?

- The clinical trial will be conducted at a hospital (clinical trial site) in the US, and will be led by a team of medical experts who have a deep knowledge of gene therapy and experience caring for individuals with Rett syndrome; there will be more than one clinical trial site
- Neurogene will provide an update once clinical trial sites are ready to begin enrolling participants
- We are early in the process of working with regulators to explore the opportunity for additional clinical trial sites outside the U.S.; it is premature to provide further information at this time

When will the clinical trial start enrolling participants?

- The NGN-401 Phase 1/2 clinical trial to dose female pediatric patients with Rett syndrome, will be initiated in 2023
- Clinical trial sites have several processes to complete before they can enroll and dose the first participant
- Given the novel and complex nature of gene therapy, this may take several months; it is typical to take 6-12 months from FDA IND clearance until the first patient is dosed
- Therefore, we do not have exact timing to share now
- As these preparatory steps near completion, we will provide an update sharing additional information including when study enrollment will begin

Can families contact someone now to express their interest in being in the clinical trial?

- The clinical trial is not yet enrolling; once information about the sites becomes available, we will share contact information with the Rett syndrome patient advocacy organizations, as well as on our website and social media channels
- Neurogene, as the sponsor of the study, is unable to keep a list of interested families due to regulatory, legal, and compliance standards related to performing a clinical trial

How can Neurogene be contacted? Is Neurogene on social media?

Neurogene contact information is:

- By phone: +1-877-237-5020
- Patients and families can reach us at: patientinfo@neurogene.com
- Healthcare providers can reach us at: medicalinfo@neurogene.com
- Our website is: www.neurogene.com

We are on social media at the following channels:

- Neurogene Inc. Facebook page: https://www.facebook.com/NeurogeneInc/
- Neurogene Inc. Twitter handle: https://twitter.com/NeurogeneInc/
- Neurogene Inc. LinkedIn profile: https://www.linkedin.com/company/NeurogeneInc

The entire Neurogene team is excited for the opportunity to advance our development program and begin our first clinical trial for Rett syndrome. We know that families are waiting for treatment options, so we will continue to work with a sense of urgency. We will share available updates on the clinical trial with the patient advocacy organizations, and through our social media channels. We remain committed to providing you with information as it becomes available. We appreciate the insights you have provided to help inform our work; it is an honor to work with this amazing community.

Sincerely,
Kimberly Trant, RN, MBA
Executive Director, Patient Advocacy and Engagement

Neurogene Inc.
535 W 24th St, 5th Floor
New York, NY 10011
www.neurogene.com

GL-RET-C-0007v1